760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Yoshinobu Koguchi(Providence Portland Medical Center), William L. Redmond(Providence St. Vincent Medical Center), Walter J. Urba(Providence Portland Medical Center), Brendan D. Curti(Providence Portland Medical Center), Noriko Iwamoto(Shimadzu (Japan)), Brian Piening(Providence College), Shu‐Ching Chang(Providence College), Takashi Shimada(Keio University)
Cited by 2
Related Papers
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
|Journal of Clinical Investigation|2004|1.4k
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Longitudinal multi-omics of host–microbe dynamics in prediabetes
|Nature|2019|620